Effect of infliximab on markers of bone metabolism in patients with rheumatoid arthritis.

被引：0
|
作者：
Vis, M
Wolbink, GJ
van Soesbergen, RM
Lodder, MC
van der Stadt, RJ
Dijkmans, BAC
Lems, WF
机构：
[1] Jan van Breemen Inst, Amsterdam, Netherlands
[2] Slotervaart Hosp, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2002年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
M371
引用
收藏
页码：S478 / S478
页数：1
相关论文
共 50 条
  • [21] Autoimmunity is not associated with antibodies to infliximab in patients with early rheumatoid arthritis.
    Rojas, JR
    Wagner, CL
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S568 - S569
  • [22] Evidence for infliximab-induced improvement of bone metabolism in psoriatic arthritis.
    Antoni, C
    Kavanaugh, A
    Krueger, GG
    Guzzo, C
    Wagner, C
    Beutler, A
    Zhou, B
    Dooley, L
    Marano, CW
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S214 - S215
  • [23] Effects of the TNF-alpha antibody infliximab on serum markers of bone turnover and mineral metabolism in patients with rheumatoid arthritis
    Dimai, HP
    Müller, T
    Eder, S
    Hermann, J
    BONE, 2001, 28 (05) : S179 - S180
  • [24] The effect of etanercept on bone metabolism in patients with rheumatoid arthritis
    Kida, D.
    Eto, Y.
    Tsukamoto, M.
    Sato, T.
    Kaneko, A.
    Ishihara, G.
    Sugishita, H.
    Saito, K.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S472 - S472
  • [25] Serum levels of parathyroid hormone and markers of bone metabolism in patients with rheumatoid arthritis. Relationship to disease activity and glucocorticoid treatment
    Jensen, T
    Hansen, M
    Madsen, JC
    Kollerup, G
    Stoltenberg, M
    Florescu, A
    Schwarz, P
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2001, 61 (06): : 491 - 501
  • [26] Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab
    Lequerre, T.
    Jouen, F.
    Brazier, M.
    Clayssens, S.
    Klemmer, N.
    Menard, J. -F.
    Mejjad, O.
    Daragon, A.
    Tron, F.
    Le Loet, X.
    Vittecoq, O.
    RHEUMATOLOGY, 2007, 46 (03) : 446 - 453
  • [27] Biochemical markers of bone metabolism in rheumatoid arthritis patients with osteoporosis.
    Moesenthin, M
    Spieler, W
    Pap, T
    Flach, W
    Kekow, J
    ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 357 - 357
  • [28] Hand bone mineral density is related to disease activity markers in patients with rheumatoid arthritis.
    Mackenzie, L
    Stewart, A
    Black, AJ
    Reid, DM
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S293 - S293
  • [29] RANKL inhibition with denosumab decreases markers of bone and cartilage turnover in patients with rheumatoid arthritis.
    Lane, N. E.
    Iannini, M.
    Atkins, C.
    Haraoui, B.
    Zhou, L.
    Tsuji, W.
    Newmark, R.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S225 - S226
  • [30] A difference in effectiveness between infliximab, etanercept and adalimumab in patients with rheumatoid arthritis.
    Kievit, Wietske
    Fransen, Jaap
    Kuper, Ina H.
    van de Laar, Mart A. F. J.
    Jansen, Tim L.
    De Rooij, Dirk jan R. A. M.
    de Gendt, Carla M.
    Ronday, Karel H.
    Brus, Herman L. M.
    van Ooijen, Piet C. M.
    van Riel, Piet C. L. M.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S309 - S310
12345